絞り込み

18384

広告

弔鐘の記憶 ある患者家族の手記 (日経サイエンス)

アルツハイマー病は妻の記憶と人生を奪い,私たち家族を苦しめた。私たちにそれを止められる手立てはなかった。医学にも――。 スタンフォード大学などでサイエンスライテ...

  1. 特集:アルツハイマー病 (日経サイエンス...
  2. [企業] 病因遺伝子の出鼻を挫く遺伝子標...
  3. 「叡王戦」異例の第9局で豊島竜王勝利「二...
  4. [企業] RocheがInflazome...

ニュース一覧

Prevalence of drug-drug interaction in atrial fibrillation patients based on a large claims data.

著者 Momo K , Kobayashi H , Sugiura Y , Yasu T , Koinuma M , Kuroda SI
PLoS One.2019 ; 14(12):e0225297.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (24view , 0users)
This study aimed to compare and determine the prevalence of drug-drug interaction (DDI) and bleeding rate in atrial fibrillation (AF) patients receiving anticoagulants in a clinical setting. We used large claims data of AF patients obtained from the Japan Medical Data Center. The prevalence of DDIs and cases leading to bleeding events were surveyed clinically relevant DDIs extracted from 1) reported from a spontaneous adverse event reporting system (Japanese Adverse Drug Events Report system; JADER) ≥4 patients; 2) DDIs cited in the package inserts of each anticoagulant (each combination assessed according to "Drug interaction 2015" list; 3) warfarin and quinolone antibiotics DDIs. DDIs were categorized the mechanisms for pharmacokinetic DDI (Cytochrome P450 (CYP) or transporter etc. that modulate blood concentration of anticoagulants)/pharmacodynamic DDI (combination with similar pharmacological actions) or both in the analysis for each patients' prescriptions obtained from a claims data. AF patients were compared between cases with and without bleeding after administered of anticoagulants. Bleeding was observed in 220/3290 (6.7%) AF patients. The bleeding rate in patients with both pharmacokinetic and pharmacodynamic DDI mechanisms (26.3%) was higher than that in patients with either mechanism (8.6% and 9.2%, respectively) or without DDIs (4.9%). The odds ratio for bleeding in AF patients with both of pharmacokinetic and pharmacodynamic was (7.18 [4.69-11.00], p<0.001). Our study concluded multi mechanism based DDIs leads serious outcome as compared to that of single mechanism based DDIs in AF patients. We determined the prevalence and frequency of bleeding for anticoagulant-related DDIs. To manage DDIs, both pharmacokinetic and pharmacodynamic DDI mechanisms should be closely monitored for initial symptoms of bleeding within the first 3 months.
PMID: 31815956 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード